Iolyx Therapeutics Announces Promising Phase II Results for ILYX-002 in Autoimmune Dry Eye Disease
ILYX-002 shows 3x greater corneal healing effect compared to current therapies on the market. Iolyx Therapeutics (California, United States), a…
AI-Powered ‘Healthcare from the Eye’ Alliance Launches at ARVO 2025
AI meets oculomics as a new coalition pushes for scalable, systemic disease screening through the eye. A new consortium of…
popular posts
latest posts